Elevance Health closes $5.2B multi-tranche notes offering; proceeds for general corporate purposes

Elevance Health, Inc.

Issued $5.2B aggregate principal across six series: 2026 (4.500%), 2030 (4.750%), 2031 (4.950%), 2035 (5.200%), 2055 (5.700%), 2064 (5.850%).
Net proceeds of approximately $5.138B after underwriting discounts and expenses.
Proceeds intended for working capital, acquisitions, debt repayment, and share repurchases.
Notes issued under existing indenture; underwriters include Citigroup, Morgan Stanley, Wells Fargo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.